Intelligent Bio Solutions Stock (NASDAQ: INBS)

Dernières nouvelles pour Intelligent Bio Solutions (NASDAQ:INBS) Stock

Intelligent Bio Solutions

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).

Intelligent Bio Solutions Inc. - Common Stock

Intelligent Bio Solutions Inc

Seaport Global analyst Jeff Campbell downgrades Altus Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) from Buy to Neutral.

News

Downgrades

Analyst Ratings

AMPS

Seaport Global Downgrades Altus Power to Neutral

Take-Two Interactive Software Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) reported third-quarter financial results after the market close on Thursday. Here&#8217;s a look at the <a href="https://www.benzinga.com/pressreleases/25/02/b43544649/take-two-interactive-software-inc-reports-results-for-fiscal-third-quarter-2025">key details from the quarter</a>.
Q3 Earnings: Take-Two reported third-quarter revenue of $1.37 billion, missing analyst estimates of $1.39 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The video game publisher reported third-quarter adjusted earnings of 72 cents per share, beating analyst estimates of 57 cents per share.
Total net bookings grew 3% year-over-year. Net Bookings from recurrent consumer spending grew&nbsp;9%&nbsp;year-over-year and accounted for&nbsp;79%&nbsp;of total Net Bookings. Take-Two noted that net bookings growth was driven by&nbsp;&#8220;significant outperformance&#8221; in&nbsp;NBA 2K, which helped offset moderation experienced in several of the company&#8217;s mobile franchises.&nbsp;
The company ended the quarter with $1.21 billion in cash and cash equivalents.
&#8220;We achieved solid results during the holiday season,&#8221; said Strauss Zelnick, chairman and CEO of Take-Two Interactive.
&#8220;Looking ahead, this calendar year is shaping up to be one of the strongest ever for Take-Two, as we plan to launch Sid Meier&#8217;s Civilization VII on Feb. 11, Mafia: The Old Country in the Summer, Grand Theft Auto VI in the Fall, and Borderlands 4.&#8221;
Outlook: Take-Two expects fourth-quarter revenue to be between $1.52 billion and $1.62 billion versus estimates of $1.54 billion. The company anticipates anywhere from a loss of 20 cents per share to positive earnings of 13 cents per share in the fourth quarter versus estimates of 6 cents per share.
Take-Two sees full-year revenue in the range of $5.57 billion to $5.67 billion versus estimates of $5.62 billion. The company anticipates a full-year loss of $4.17 to $4.50 per share versus estimates for a loss of $4.47 per share, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;As we continue to deliver hits, we remain highly confident that we will achieve sequential increases in, and record levels of, Net Bookings in Fiscal 2026 and 2027,&#8221; Zelnick said.
Investors appear to be responding favorably to the commentary on the timing of Grand Theft Auto VI&#8217;s highly anticipated release. The company also said it will release PGA Tour 2K25 on Feb. 28 and WWE 2K25 on March 14. 
TTWO Price Action: <a href="http://benzinga.com/quote/ttwo">Take-Two shares</a> were up 5.91% after hours, trading at $193.90 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Earnings

Gaming

Guidance

After-Hours Center

Movers

TTWO

Take-Two Interactive Software Q3 Earnings: Revenue Miss, EPS Beat, Bookings Up 3%, Grand Theft Auto IV On Track For Fall Release

Higher Innovation, an Austin-based cannabis technology company, recently introduced the HotBox Portable Air Purifier, a mid-sized device (7.75&#8243; L x 7.75&#8243; W x 8&#8243; H), roughly the size of a small kitchen appliance –like a toaster, aimed at eliminating cannabis smoke and odors in real-time. Retailing at $249, the American-made purifier claims to drastically reduce airborne contaminants, appealing to consumers who need discretion without compromising their lifestyle.
The device has already caught the attention of cultural icon Mike Tyson, who partnered with Higher Innovation to launch the TYSON 2.0 HotBox—a branded version that debuted at MJBizCon 2024 in Las Vegas. But beyond the celebrity endorsement, does this gadget truly deliver on its promises, and who really needs it?
<h3 class="wp-block-heading">Who Is The HotBox For?</h3>
Cannabis has become mainstream, but stigma remains. While some proudly display their stash, others prefer discretion—whether for personal reasons or external pressures. The HotBox Portable Air Purifier caters to several key demographics:
<ul>
<li>Parents who use cannabis but want to keep their homes odor-free.</li>
<li>Apartment dwellers looking to avoid complaints from neighbors.</li>
<li>Medical cannabis patients who want to eliminate secondhand smoke.</li>
<li>Remote workers who don't want their home office to smell like a dispensary.</li>
<li>Users in restrictive housing—whether due to landlords, roommates, or local laws.</li>
</ul>
With cannabis still illegal in many jurisdictions, reducing odor isn't just about comfort—it can be a legal safeguard. "Cannabis is an extremely difficult smell to tackle," Higher Innovation CEO Ashley Ciccel says. "We address the problem with a two-pronged approach: capture and conceal." The HotBox captures airborne smoke, while the included Smell Away spray further neutralizes residual odors.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="619" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06163116/Higher-Innovation-HotBox-Smoke-T20.-.png" alt="Hotbox Tyson" class="wp-image-770355" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06163116/Higher-Innovation-HotBox-Smoke-T20.-.png 619w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06163116/Higher-Innovation-HotBox-Smoke-T20.--226x300.png 226w" sizes="(max-width: 619px) 100vw, 619px" /></figure>
<h3 class="wp-block-heading">Performance And Features</h3>
The HotBox combines a three-layer filtration system to purify the air:
<ul>
<li>Carbon Pre-filter: Captures larger smoke particles.</li>
<li>HEPA Particulate Filter: Eliminates fine airborne contaminants.</li>
<li>2" Activated Carbon Pellets: Absorbs odors at a molecular level.</li>
</ul>
Positioned near the smoke source, the device effectively captures exhaled smoke, preventing it from spreading. "To use, position the device to capture as much smoke as possible… exhale into the inlet… leave the unit running to continue purifying the air," Ciccel explains. The purifier also comes with a lockable smell-proof bag, making it easy to store discreetly.
<h3 class="wp-block-heading">Does It Work? Hands-On Testing</h3>
In real-world testing, the HotBox performs best in mid-sized spaces like a bedroom or living room. It eliminates most odors quickly, but its effectiveness depends on placement. If you blow smoke directly into the machine, it works efficiently, reducing smells within minutes. However, if smoke spreads throughout the room, it takes longer to fully remove lingering odors. The additional Smell Away spray can help accelerate odor elimination when needed.
The unit runs for six hours on battery power or can be plugged into a standard 120V outlet. With four fan speeds and a coverage area of up to 100 square feet, it's ideal for small apartments, home offices, or personal spaces.
<h3 class="wp-block-heading">The Verdict And Alternatives</h3>
The HotBox Portable Air Purifier is an effective, well-designed device for smoke-conscious cannabis users who value discretion. It's not necessarily a full-room air purifier but rather a personal smoke filtration system that works best when used near the source.
At $249, the price is on the high end for an odor-management device. However, the combination of filtration, discretion and targeted performance makes it a compelling option for those who need a reliable way to keep their spaces smoke-free.
For those looking for alternatives, options like sploofs (personal smoke filters like SmokeBuddy or Philter Labs), HEPA-based home air purifiers, such as Levoit or Dyson models, and activated charcoal bags can also help reduce odors at varying levels of effectiveness. However, none of these alternatives offer the direct smoke capture feature that the HotBox provides.
As cannabis culture evolves, innovations like the HotBox reflect a growing demand for products that blend lifestyle with functionality.
Courtesy photo

Cannabis

We Tested Mike Tyson's Weed Odor Eliminator: Does The HotBox Air Purifier Really Remove Cannabis Smell From The Air?

Telsey Advisory Group analyst Cristina Fernandez maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Market Perform and maintains $80 price target.

Price Target

Telsey Advisory Group Maintains Market Perform on Nike, Maintains $80 Price Target

The company issued $750 million of depositary shares, each representing a 1/100th ownership interest in a share of its 6.450% Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series K with a liquidation preference of $100,000 per share.

State Street Plans Issuance Of Preferred Stock

Chardan Capital analyst Keay Nakae maintains Coya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) with a Buy and maintains $14 price target.

COYA

Chardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target

United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) has outperformed the market over the past 15 years by 1.49% on an annualized basis producing an average annual return of 13.68%. Currently, United Airlines Holdings has a market capitalization of $35.86 billion. 
Buying $100 In UAL: If an investor had bought $100 of UAL stock 15 years ago, it would be worth $697.00 today based on a price of $109.05 for UAL at the time of writing.
<h3>United Airlines Holdings's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738882810_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning United Airlines Holdings Stock In The Last 15 Years

Barrington Research analyst Alexander Paris maintains Affiliated Managers Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMG#NYSE">AMG</a>) with a Outperform and raises the price target from $200 to $215.

Barrington Research Maintains Outperform on Affiliated Managers Group, Raises Price Target to $215

Exane BNP Paribas analyst Moses Sutton upgrades Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) from Underperform to Neutral and announces $9 price target.

Upgrades

ARRY

Exane BNP Paribas Upgrades Array Technologies to Neutral, Announces $9 Price Target

Microchip Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) reported its third-quarter financial results after Thursday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/02/g43545040/microchip-technology-announces-financial-results-for-third-quarter-of-fiscal-year-2025">details from the report. </a>
The Details: Microchip reported quarterly earnings of 20 cents per share, which missed the analyst consensus estimate of 28 cents. Quarterly revenue came in at $1.02 billion which missed the analyst consensus estimate of $1.06 billion and is a decrease from sales of $1.76 billion from the same period last year.
Read Next: <a href="https://www.benzinga.com/general/social-media/25/02/43535256/palantir-adds-elon-musks-ai-chatbot-grok-to-aip">Palantir Adds Elon Musk&#8217;s AI Chatbot Grok To AIP</a>
&#8220;Our December quarter performance reflects the need for the decisive steps we are taking to realign our business, as revenue declined to $1.026 billion and inventory levels reached 266 days,&#8221; said Steve Sanghi, Microchip&#8217;s CEO and president.
&#8220;Since returning as CEO in November, we have already initiated several key actions, including restructuring our manufacturing footprint, adjusting our channel strategy and intensifying our customer engagement. Our initial assessment indicates clear areas for operational enhancement, and we are taking a methodical yet urgent approach to evaluating all aspects of our business and implementing necessary changes to strengthen our competitive position,&#8221; Sanghi added. 
Outlook: Microchip sees fourth-quarter earnings in a range of five cents to 15 cents per share, versus the 28 cent estimate, and revenue in a range of $920 million to $1 billion, versus the $1.06 billion estimate.
MCHP Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Microchip Technology shares are down 6.80% after hours at $49.50 on Thursday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43512137/ford-shares-skid-after-q4-report-details">Ford Shares Skid After Q4 Report: Details</a></li>
</ul>
Image: Shutterstock

Tech

MCHP

Microchip Technology Shares Fall After Worse-Than-Expected Q3 Report

RB Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBA#NYSE">RBA</a>) has outperformed the market over the past 20 years by 3.02% on an annualized basis producing an average annual return of 11.4%. Currently, RB Global has a market capitalization of $16.78 billion. 
Buying $100 In RBA: If an investor had bought $100 of RBA stock 20 years ago, it would be worth $860.81 today based on a price of $91.00 for RBA at the time of writing.
<h3>RB Global's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738882006_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning RB Global Stock In The Last 20 Years

The offering consisting of $1.1 billion aggregate principal amount of 5.15% senior notes due 2030 and $900 million aggregate principal amount of 5.70% senior notes due 2035.
MPC intends to use the net proceeds from this offering to repay, redeem or otherwise retire its outstanding $1.25 billion aggregate principal amount of 4.700% senior notes due May 2025 and for general corporate purposes.

Offerings

Marathon Petroleum Prices $2B Of Unsecured Senior Notes In Public Offering

Macquarie analyst Eugene Hsiao upgrades Li Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) from Neutral to Outperform.

Macquarie Upgrades Li Auto to Outperform

IBEX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBEX#NASDAQ">IBEX</a>) raises FY2025 sales outlook from $515.00 million-$525.00 million to $525.00 million-$535.00 million vs $523.00 million estimate.

IBEX

IBEX Raises FY2025 Sales Guidance from $515.00M-$525.00M to $525.00M-$535.00M vs $523.00M Est

IBEX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBEX#NASDAQ">IBEX</a>) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.51 by 15.69 percent. This is a 34.09 percent increase over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $140.68 million which beat the analyst consensus estimate of $134.63 million by 4.50 percent. This is a 6.07 percent increase over sales of $132.63 million the same period last year.

Earnings Beats

IBEX Q2 Adj $0.59 Beats $0.51 Estimate, Sales $140.68M Beat $134.63M Estimate

DAKT

Daktronics Shareholder Alta Fox Capital Says It Remains Convinced That Company Is Meaningfully Undervalued; Says Company's Claims Are Misleading

FirstCash Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCFS#NASDAQ">FCFS</a>) has outperformed the market over the past 20 years by 2.86% on an annualized basis producing an average annual return of 11.24%. Currently, FirstCash Hldgs has a market capitalization of $5.01 billion. 
Buying $100 In FCFS: If an investor had bought $100 of FCFS stock 20 years ago, it would be worth $856.03 today based on a price of $111.84 for FCFS at the time of writing.
<h3>FirstCash Hldgs's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738881116_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FCFS

Here's How Much $100 Invested In FirstCash Hldgs 20 Years Ago Would Be Worth Today

Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) reported its fourth-quarter financial results after Thursday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/02/b43544380/expedia-group-reports-fourth-quarter-and-full-year-2024-results">details from the report. </a>
The Details: Expedia Group reported quarterly earnings of $2.39 per share, which beat the analyst consensus estimate of $2.02. Quarterly revenue clocked in at $3.18 billion, which beat the analyst consensus estimate of $3.07 billion and is an increase over revenue of $2.89 billion from the same period last year.
<ul>
<li>Booked room nights grew 12% in the fourth quarter year-over-year and 9% for full year 2024.</li>
<li>Total gross bookings and revenue grew 13% and 10% year-over-year, respectively in the fourth quarter. </li>
<li>Full year gross bookings and revenue both grew 7% compared to 2023.</li>
<li>B2C and B2B gross bookings growth accelerated 5 points to 9% and 24% respectively in the fourth quarter.</li>
<li>Lodging gross bookings grew 12% year-over-year in the fourth quarter; hotel bookings were up 14%.</li>
<li>Expedia reinstated a quarterly dividend of 40 cents starting in March 2025.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/general/social-media/25/02/43535256/palantir-adds-elon-musks-ai-chatbot-grok-to-aip">Palantir Adds Elon Musk&#8217;s AI Chatbot Grok To AIP</a>
&#8220;Our fourth quarter results exceeded our expectations and reflect continued strong execution and better-than-expected travel demand. All three of our core consumer brands achieved bookings growth and we further accelerated growth in our B2B business. These results contributed to a solid full year 2024 for us,&#8221; said Ariane Gorin, CEO of Expedia Group. 
&#8220;The reinstatement of our quarterly dividend reflects our confidence in our long-term outlook and commitment to shareholder returns,&#8221; Gorin added. 
EXPE Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Expedia shares are up 8.62% after hours at $187.12 on Thursday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43512137/ford-shares-skid-after-q4-report-details">Ford Shares Skid After Q4 Report: Details</a></li>
</ul>
Photo: Shutterstock

Travel

General

EXPE

Expedia Stock Rallies On Better-Than-Expected Q4 Report: Here's Why

McEwen Mining Intends To Offer $85M Of Convertible Senior Notes Due 2030 In Private Placement

Regarding Aptar's outlook, CEO stated, "We anticipate 2025 to be another strong year for Aptar. Having said that, in the first quarter we expect significant negative impacts from foreign currencies and a higher effective tax rate compared to the prior year quarter, as well as softer demand in certain end markets."

Aptar Expects Q1 EPS, Ex. Any Restructuring Expenses, Changes In Fair Value Of Equity Investments And Acquisition Costs, Of $1.11 - $1.19, Est $1.29

Intelligent Bio Solutions (INBS) announced the submission of its 510(k) premarket notification to the US Food and Drug Administration, FDA, for cle...

Intelligent Bio Solutions announces 510k submission to FDA on FDSS

Intelligent Bio Solutions ( ($INBS) ) just unveiled an update. Intelligent Bio Solutions Inc. has submitted a 510(k) premarket notification to the ...

Intelligent Bio Solutions Submits FDA Premarket Notification

Intelligent Bio Solutions (INBS) announced that Princebuild has adopted INBS' Intelligent Fingerprinting Drug Screening System, IFDSS. Princebuild ...

Intelligent Bio Solutions partners with Princebuild, adopts IFDSS

Intelligent Bio Solutions (INBS) announced the strengthening of its foothold throughout Europe and the Middle East through its partnership with IVY...

Intelligent Bio Solutions partners with IVY Diagnostics

Intelligent Bio Solutions ( ($INBS) ) has issued an announcement. On January 28, 2025, Intelligent Bio Solutions announced a significant partnershi...

Intelligent Bio Solutions Partners with IVY Diagnostics

Intelligent Bio Solutions ( ($INBS) ) has provided an announcement. On January 29, 2025, Intelligent Bio Solutions Inc. announced that Quantum Traf...

Intelligent Bio Solutions Expands with UK Partnership

Intelligent Bio Solutions (INBS) announced plans for a major upgrade to its Intelligent Fingerprinting Drug Screening System. The system upgrade wi...

Intelligent Bio announces upgrade to Intelligent Fingerprinting Drug Screening

Intelligent Bio Solutions ( ($INBS) ) has shared an announcement. On January 31, 2025, Intelligent Bio Solutions announced plans to upgrade its Int...

Intelligent Bio Solutions Expands Fingerprinting System Globally

Intelligent Bio Solutions reports preliminary Q2 revenue $0.61M

Expects Q2 Gross profit to increase 32.6% from $0.43 million to $0.57 million for the six months ended December 31, 2024. "Our strong financial per...

Intelligent Bio Solutions reports preliminary Q2 revenue $610,000

INBS

Health Care

Press Releases

Intelligent Bio Solutions to Participate in the Noble Capital Markets' 20th Annual Emerging Growth Equity Conference

Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results

Intelligent Bio Solutions to Host Virtual Fireside Chat on Wednesday, December 11th at 4:30 p.m. ET

Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology

Intelligent Bio Solutions Partners with Princebuild to Transition from Saliva Testing to Fingerprint Sweat-Based Drug Screening Across its Seven UK Sites

Comments

Intelligent Bio Solutions

Actualités

Dernières nouvelles pour Intelligent Bio Solutions (NASDAQ:INBS) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL